β-Nerve growth factor (β-NGF) mRNA expression in the Parkinsonian adrenal gland

Silani, Vincenzo; Pizzuti, Antonio; Falini, Andrea; Borsani, Giuseppe; Rugarli, Elena I.; Melo, C.A. de O.; Sidoli, Alessandro; Villani, Flavio; Baralle, F.; Scarlato, G.

doi:10.1016/0014-4886(91)90172-9

Cited by 12 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…β-NGF has neuroprotective effects in cholinergic neurons that project to the cerebral cortex and hippocampus. [29][30][31] Changes in the cholinergic tone in the striatum and the cholinergic nuclei have been described as highly relevant for different symptoms in PD, including cognitive decline, sleep disorders, and gait dysfunction. 32 FGF21 is regarded as an MQC marker and is known as a potent regulator of blood glucose.…”

Section: Neurodegeneration Markersmentioning

confidence: 99%

Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease

Bartl¹,

Dakna²,

Schade

et al. 2022

Movement Disorders

View full text Add to dashboard Cite

Background Recent studies point toward a significant impact of cardiovascular processes and inflammation on Parkinson's disease (PD) progression. Objective The aim of this study was to assess established markers of neuronal function, inflammation, and cardiovascular risk by high‐throughput sandwich immune multiplex panels in deeply phenotyped PD. Methods Proximity Extension Assay technology on 273 markers was applied in plasma of 109 drug‐naive at baseline (BL) patients with PD (BL, 2‐, 4‐, and 6‐year follow‐up [FU]) and 96 healthy control patients (HCs; 2‐ and 4‐year FU) from the de novo Parkinson's cohort. BL plasma from 74 individuals (37 patients with PD, 37 healthy control patients) on the same platform from the Parkinson Progression Marker Initiative was used for independent validation. Correlation analysis of the identified markers and 6 years of clinical FU, including motor and cognitive progression, was evaluated. Results At BL, 35 plasma markers were differentially expressed in PD, showing downregulation of atherosclerotic risk markers, eg, E‐selectin and ß2‐integrin. In contrast, we found a reduction of markers of the plasminogen activation system, eg, urokinase plasminogen activator. Neurospecific markers indicated increased levels of peripheral proteins of neurodegeneration and inflammation, such as fibroblast growth factor 21 and peptidase inhibitor 3. Several markers, including interleukin‐6 and cystatin B, correlated with cognitive decline and progression of motor symptoms during FU. These findings were independently validated in the Parkinson Progression Marker Initiative. Conclusions We identified and validated possible PD plasma biomarker candidates for state, fate, and disease progression, elucidating new molecular processes with reduced endothelial/atherosclerotic processes, increased thromboembolic risk, and neuroinflammation. Further investigations and validation in independent and larger longitudinal cohorts are needed. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

show abstract

Section: Neurodegeneration Markersmentioning

confidence: 99%

Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease

Bartl¹,

Dakna²,

Schade

et al. 2022

Movement Disorders

View full text Add to dashboard Cite

show abstract

“…NGF has been implicated in maintaining and regulating the septohippocampal pathway, which is involved in learning and memory [121–123]. NGF is also present in the human SN [124] and in the adrenal gland [125]. NGF concentrations are decreased in the SN of the PD and in a rat model of PD [69, 126].…”

Section: Nongenomic Role Of Vitamin D In Parkinson's Diseasementioning

confidence: 99%

Role of Vitamin D in Parkinson’s Disease

Lương

Nguyễn

2012

ISRN Neurology

View full text Add to dashboard Cite

Parkinson's disease (PD) is the second most common form of neurodegeneration in the elderly population. Clinically, it is characterized by tremor, rigidity, slowness of movement, and postural imbalance. A significant association between low serum vitamin D and PD has been demonstrated, suggesting that elevated vitamin D levels might provide protection against PD. Genetic studies have helped identify a number of proteins linking vitamin D to PD pathology, including the major histocompatibility complex (MHC) class II, the vitamin D receptor (VDR), cytochrome P450 2D6 (CYP2D6), chromosome 22, the renin-angiotensin system (RAS), heme oxygenase-1 (HO-1), poly(ADP-ribose) polymerase-1 gene (PARP-1), neurotrophic factor (NTF), and Sp1 transcription factor. Vitamin D has also been implicated in PD through its effects on L-type voltage-sensitive calcium channels (L-VSCC), nerve growth factor (NGF), matrix metalloproteinases (MMPs), prostaglandins (PGs) and cyclooxygenase-2 (COX-2), reactive oxygen species (ROS), and nitric oxide synthase (NOS). A growing body of evidence suggests that vitamin D supplementation may be beneficial for PD patients. Among the different forms of vitamin D, calcitriol (1,25-dihydroxyvitamin D3) is best indicated for PD, because it is a highly active vitamin D3 metabolite with an appropriate receptor in the central nervous system (CNS).

show abstract

“…β-NGF is a trophic factor for sympathetic and sensory fibers found in the peripheral nervous system and in the central nervous system in cholinergic neurons projecting to the cerebral cortex and hippocampus. β-NGF has neuroprotective effects in cholinergic neurons [35][36][37]. Therefore, the reduction in β-NGF levels may indicate a more advanced neuronal cell loss in MSA.…”

Section: Discussionmentioning

confidence: 99%

Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms

et al. 2020

View full text Add to dashboard Cite

Background: Parkinson's disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression. Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed. Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01). Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.

show abstract

β-Nerve growth factor (β-NGF) mRNA expression in the Parkinsonian adrenal gland

Cited by 12 publications

References 28 publications

Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease

Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease

Role of Vitamin D in Parkinson’s Disease

Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms

Contact Info

Product

Resources

About